
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health Inc. has demonstrated a significant stock price increase of 34% since the 1Q24 report, substantially outpacing the S&P index's 6% rise, indicating strong market confidence in the company's growth prospects. The organization has prioritized profitable growth and maintained a conservative approach to risk accrual in its Accountable Care Organization (ACO) programs, enhancing its operational visibility and stability. With an expected growth rate of over 15% and ongoing improvements in EBITDA as the company shifts Medicare and Medicaid patients to a full-risk model, combined with strong brand recognition, Astrana Health is positioned for continued financial success.
Bears say
Astrana Health Inc faces significant challenges, including a notable 40,000-member decline in Care Partners enrollment, which complicates its overall member growth trajectory. Negative trends in key performance metrics, alongside potential setbacks in provider value-based care implementations and the impact of Medicaid redeterminations, heighten the risk of decreased margins and stagnant revenue growth. Furthermore, competition in the value-based care sector and uncertainties related to large partnerships and healthcare utilization further contribute to a cautious outlook for the company.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares